Kornimate/medical-research-clean huggingface dataset:
a 1-year trial to inform about long-term exposure to eptinezumab in participants with chronic cluster headache (cch)

Conditions: Chronic Cluster Headache

Summary: the main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.

the participants who take part in this trial will be asked to stay in the trial for about a year. the participants will be asked to visit the trial site 7 times during the trial. in between trial site visits, they will have scheduled phone calls with the trial site staff. they will also be asked to keep track of their cluster headaches at home with a headache diary.

Eligibility criteria:
inclusion criteria: * the participant has a diagnosis of cch as defined by international headache society (ihs) international classification of headache disorders third edition (ichd-3) classification with a history of cch of at least 12 months prior to the screening visit. * the participant has a medical history of onset of cluster headache at ≤50 years of age. * the participant has an adequately documented record of previous abortive, transitional and preventive medication use for cch, for at least 12 months prior to the screening visit. * the participant is able to distinguish cluster headache attacks from other headaches (such as tension-type headaches, migraine). exclusion criteria: * the participant has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (cgrp) pathway (anti-cgrp monoclonal antibodies \[mabs\] and gepants). * the participant has confounding and clinically significant pain syndromes (for example, fibromyalgia, complex regional pain syndrome). * the participant has a history or diagnosis of chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache, chronic migraine or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), recurrent painful ophthalmoplegic neuropathy, migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or longer than 1 hour). * participants with a lifetime history of psychosis, bipolar mania, or dementia. participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening visit. * the participant has attempted suicide or is, at screening visit, at significant risk of suicide. * the participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). other inclusion and exclusion criteria may apply.
reveal af: incidence of af in high risk patients

Conditions: Atrial Fibrillation

Summary: this study is to determine, through continuous monitoring with the reveal implantable cardiac monitor (icm), the incidence of atrial fibrillation (af) in patients suspected to be at high risk for having af and to understand how physicians manage these patients after af has been detected. this study will also seek to identify what patient characteristics are most predictive of developing af.


Eligibility criteria:
inclusion criteria: * patient meets the approved indications to receive the reveal icm * patient is suspected, based on symptomatology and/or demographics, of having atrial fibrillation or at high risk of having af, as determined by the clinical investigator * patient has a congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack (tia) or thromboembolism (doubled) (chads2) score ≥ 3 or has a chads2 score = 2 with at least one of the following documented: renal impairment (gfr 30-60 ml/min), sleep apnea, coronary artery disease, or chronic obstructive pulmonary disease. note: stroke/tia criterion as part of the chads2 score for this trial is limited to either an ischemic stroke or tia, which occurred more than one year prior to enrollment. * patient is 18 years of age or older * patient has a life expectancy of 18 months or more * patient, or legally authorized representative, is willing to sign and date the consent form * patient is willing and able to be remotely monitored (i.e., eligible for enrollment into the medtronic carelink network) exclusion criteria: * patient has a documented history of af or atrial flutter * patient had an ischemic stroke or tia within past year prior to enrollment * patient has a history of a hemorrhagic stroke * patient is currently implanted with an implantable pulse generator (ipg), implantable cardioverter defibrillator (icd), cardiac resynchronization therapy pacemaker (crt-p), or cardiac resynchronization therapy defibrillator (crt-d) device * new york heart association (nyha) class iv heart failure patient * patient had heart surgery within previous 90 days prior to enrollment * patient had a myocardial infarction (mi) within the previous 90 days prior to enrollment * patient is taking chronic immuno-suppressant therapy * patient is taking an anti-arrhythmic drug * patient is contraindicated for long term anticoagulation medication * patient is taking a long-term anticoagulation medication * any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional / psychological diagnosis) * patient is enrolled in another study that could confound the results of this study, without documented pre-approval from medtronic study manager * patient has a creatinine clearance \<30 ml/min or is on dialysis
effect of breathıng exercıse applıed to indıvıduals wıth copd on respıratory functıon, dyspnea and qualıty of lıfe

Conditions: Quality of Life

Summary: purpose of the research this research was designed to determine the effect of breathing exercise applied to individuals diagnosed with copd on respiratory function, dyspnea and quality of life. hypotheses of the research h0a: breathing exercise applied to individuals diagnosed with copd has no effect on the respiratory function test fev1/fvc. h1a: breathing exercise applied to individuals diagnosed with copd has an effect on the respiratory function test fev1/fvc. h0b: breathing exercise applied to individuals diagnosed with copd has no effect on dyspnea. h1b: breathing exercise applied to individuals diagnosed with copd has an effect on dyspnea. h0c: breathing exercise applied to individuals diagnosed with copd has no effect on quality of life. h1c: breathing exercise applied to individuals diagnosed with copd has an effect on the quality of life.


Eligibility criteria:
inclusion criteria: * diagnosed with copd for at least 1 year, confirmed by pulmonary function test * those who voluntarily accepted to participate in the research * those aged 18 and over, * individuals who have access to the hospital exclusion criteria: * in copd exacerbation period, * having a neurological or psychiatric diagnosis, * those with obesity, * those with physical disabilities (vision, hearing, walking, etc.), * those who are pregnant, * illiterate * diagnosed with another disease that significantly affects the respiratory system (scoliosis, lung cancer, abdominal tumor, etc.). * patients who have previously participated in an exercise program will be excluded from the study.

Keywords: dyspnea copd breathing exercise pranayama respiratory function quality of life.
blue protocol assessment

Conditions: Dyspnea; Emergencies

Summary: acute dyspnea is a common disease in emergency medicine. mortality remains high is estimated at 15%. one third of initial diagnoses before paraclinical examination are estimated to be inaccurate. lung ultrasound is a quick and immediate examination. also, it is provided and performed at the bedside. the " blue protocol " was designed by daniel a. lichtenstein as a diagnostic aid in dyspneic patients. it allows to obtain a diagnostic in more than 90% of acute dyspnea. however there is no validation in emergency medicine. the main purpose is to evaluate the interest of the " blue protocol "in the management and orientation of the dyspneic patient


Eligibility criteria:
inclusion criteria: * age over 18 years * dyspneic patient requiring management by an emergency physician * information given and no patient opposition. exclusion criteria: * patient under a legal protection measure * lack of social security

Keywords: dyspnea lung ultrasound emergency medicine blue protocol
identification of risk factors for atrial fibrillation after ablation of an atrial flutter by radiofrequency of the cavotricuspid isthmus.

Conditions: Flutter

Summary: atrial flutter is a common condition that is effectively treated by ablation using radiofrequency. due to its feasibility, effectiveness and low procedural risk, radiofrequency ablation is a first-line treatment of atrial flutter. several studies have been published concerning the factors associated with the occurrence of atrial fibrillation during or after flutter ablation, in patients with and without clinical history of atrial fibrillation. 26 to 46% of patients are likely to develop it, according to ecg or holter diagnoses. the figure rises to more than 50% with a diagnosis with an implantable loop recorder. in patients without a prior history of atrial fibrillation before ablation, anticoagulants are routinely administered 4-6 weeks after flutter removal by most cardiologists. although there are no specific guidelines for anticoagulation after flutter ablation, it is currently recommended to treat the patient as for atrial fibrillation. it is therefore crucial to identify in advance patients at high risk of atrial fibrillation after flutter ablation, in order to assess the appropriateness of maintaining oral anticoagulant therapy. the objectives of this study are: * to evaluate the frequency and identify the factors predicting the occurrence of atrial fibrillation after flutter ablation * to determine the risk of a stroke occurring in patients with atrial fibrillation after flutter ablation. the database consists in patients of the chu brugmann hospital treated between 1996 and 2018.


Eligibility criteria:
inclusion criteria: patients treated at the chu brugmann hospital for flutter ablation by radiofrequency between 1996 and 2018. exclusion criteria: none
epidemiology of conjunctivitis in the emergency department

Conditions: Acute Conjunctivitis

Summary: epidemiology of conjunctivitis in the emergency department of a reference ophthalmological hospital in goiânia.

the purpose of this study was to determine the epidemiology of ocular emergencies in a reference ophthalmological hospital in goiânia, with emphasis on acute infectious conjunctivitis, morbidity with a higher incidence in this service. it aims to delineate the main etiologies found among infectious conjunctivitis and to compare them with those found in several other reference services in ophthalmology.

Eligibility criteria:
inclusion criteria: * all those patients who were submitted to a initial care performed by the first year resident (r1) of the hospital and who were admitted during the period described. exclusion criteria: * the patients who were admitted in the emergency department outside this period * the patients who were not attended by a first year resident (r1) * the patients who did not have all the data filled in the medical record * the patients who needed to return, being attended in the hospital more than once.
intercostal nerve cryoablation for postoperative pain management

Conditions: Pain, Postoperative

Summary: the purpose of the study is to assess the efficacy of intercostal nerve cryoablation on the magnitude and duration of postoperative pain control both in patients undergoing thoracoabdominal incisions for the descending or thoracoabdominal aortic aneurysm repair.


Eligibility criteria:
inclusion criteria: * descending/thoracoabdominal incision is planned * there is reasonable expectation that the patient will be extubated within 48 hours after surgery exclusion criteria: * the patient has a known allergy to morphine or any opioid * the patient has a known chronic pain disorder or takes daily opioid medication \> 1 month prior to surgery * the surgeon/anesthesiologist concludes that the period for intubation will be likely be for more than 48 hours after surgery there is anticipated difficulty communicating pain status due to language or other barriers at the investigator discretion.

Keywords: cryoablation
clinical impact of non-invasive hemodynamic monitoring

Conditions: Heart Failure

Summary: study details what is the study design? (eg, randomized, double-blind) observational prospective study what are the overall objectives of the study? this project is designed to assess the feasibility of using a non-invasive hemodynamic monitoring device in heart failure outpatient clinics. there will be no alteration to patient management for this study. rather this study seeks to assess the utility of the device by evaluating for the parameters obtained from the device to hospital admission. how your research will contribute to the advancement of scientific knowledge? ☒this study will confirm/strengthen existing knowledge. ☒this study will test a completely novel hypothesis. ☒this study will explore novel endpoints. ☐other \[please describe\]:

b. background: nearly five million americans experience heart failure (hf) and greater than 250,000 die annually. 1 the prevalence has continued to increase with the aging of the us population and hf is now the leading cause of hospitalization among adults \>65 in the united states. despite remarkable improvements in medical therapy, the prognosis of patients with myocardial failure remains poor, with almost 20% of patients dying within 1 year of initial diagnosis and \> 80% 8-year mortality. 2 in addition patients who are admitted to the hospital for heart failure have over a 50% readmission rate within six months of discharge. 3,4 these patients require routine clinical care and often require diagnostic and therapeutic procedures. this project seeks to assess if the use of hemodynamic (hd) monitoring technologies (clearsight/nexfin) that are currently used in the intraoperative and critical care settings can provide utility by demonstrating associations between alterations in a patients hd values to the likelihood of hospital admission. the non-invasive hd device utilized (nexfin, edwards lifesciences, irvine, ca) provided flow-guided cardiovascular parameters that were captured for each clinic visit for up to 24 months. analysis was performed between the most recent prior clinic visits for patients who were hospitalized for hf exacerbation to those who were not hospitalized. hd data was not used to guide clinical care. a cox hazard model using a log transformation of hd variables as the covariates, was applied to describe hospital admission.

Eligibility criteria:
inclusion criteria: * patients seen in loma linda heart failure clinics classified as new york heart association (nyha) functional classification of 3 or greater. exclusion criteria: * age \< 18 years of age, * pregnancy, * known severe peripheral artery disease, * poor perfusion to fingers (as defined as a perfusion index less than 0.5%- www.masimo.com), * history of raynaud's, * refusal to provide written consent.
prospective study of 3 phone assistance strategies to achieve a continuous cardiac massage

Conditions: Cardiac Arrest

Summary: this study must evaluate the benefit of a continuous audio guidance on the effectiveness of mce directed by a volunteer. the evaluation of the mce for this study is based on both quantitative criteria (based on the recommendations erc 2010) * frequency * depth of chest compressions. this study compares two methods of continuous audio guide (one arm with an audio continuous guidance method by the regulator and second arm with an audio continuous guidance method by the controller relayed by an audio) to a method of incentive mce based on a unique set made by the regulator(control arm).


Eligibility criteria:
inclusion criteria: - healthy volunteers from the general population understanding the french language. exclusion criteria: * major physical disability; * do not speak french * first aid training under one year

Keywords: external cardiac massage, medical hotline,
observational study of correlation between recurrent basal cell carcinoma and localisation

Conditions: Basal Cell Carcinoma

Summary: .during one year all the resected basal cell carcinomas (bcc) analyzed in montpellier university hospital anatomopathology unit were included in this study. localisation and histological characteristics were collected. all the recurrences of bcc were searched from the medical records (or histopathology request form). from 804 bcc, 48 were recurrent bcc with or without complete first resection. patients with recurrent bcc were contacted to obtain agreement and more informations about the first resection and some clinical informations like sun exposure and phototype. the statistical analysis focused on the localisation of recurrent bcc (with a complete first resection) compared to localisations of primary bcc in this population. the goal was to identified localisations with an increased risk of recurrences.


Eligibility criteria:
cohort : inclusion criteria: - patients with resected bcc exclusion criteria: * biopsies of bcc, * revised surgery of incomplete resection. cases : inclusion criteria: -recurrent bcc with complete first resection exclusion criteria: - recurrent bcc with incomplete first resection, patients with gorlin syndrome (a genetic disease that increase risk of bcc)

Keywords: resection of bcc (basal cell carcinoma) recurrence of bcc (basal cell carcinoma) localisation
relative bioavailability study on a single dose of gw842166x in healthy male and female subjects.

Conditions: Healthy Subjects

Summary: gw842166x is a selective non-cannabinoid cb2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. the purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of gw842166x in healthy male and female volunteers.


Eligibility criteria:
inclusion criteria: * body weight \>50 kg and bmi within the range 18.5-29.9 kg/m2 inclusive. * healthy as judged by a responsible physician. exclusion criteria: * positive pre-study urine screen for drugs of abuse or alcohol breath test.

Keywords: gw842166, healthy volunteers, inflammatory pain.
effects of dolutegravir based regimen on hiv-1 reservoir and immune activation

Conditions: HIV-1 Infection

Summary: we aim at comparing markers of hiv reservoir, monocyte function and immune activation between antiretroviral therapy (art)-naïve (chronic infection or primary infection), art-controlled or art-failing hiv infected adults initiating a dolutegravir (dtg)-based regimen. the investigators' purpose is to measure cell associated hiv-1 dna, monocyte function \[soluble cd14 (scd14), soluble cd163 (scd163)\], and immune activation \[neopterine, interleukin-6 (il-6) and high-sensitivity c-reactive protein (hscrp)\] biomarkers at different time points between baseline and week 48 post dtg-based regimen initiation in each group.


Eligibility criteria:
inclusion criteria: * male or female aged from de 18 to 80 years * patient starting a dtg-regimen * patients agreeing to use methods of birthcontrol while on the study and during the 6 weeks after stopping dtg treatment * signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening exclusion criteria: * women who are pregnant or breastfeeding * hbv or hcv coinfection * participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted * documented resistance to dtg * allergy or intolerance to the study drugs or their components or drugs of their class * any acute or verified grade 4 laboratory abnormality (with the exception of grade 4 lipids) at screening. * coadministration with dofelitide

Keywords: hiv reservoir hiv-1 dna immune activation monocyte function activation biomarkers
pharmacokinetic study of vhx-896 and iloperidone tablets under steady-state conditions

Conditions: Schizophrenia; Bipolar I Disorder

Summary: study to compare the pharmacokinetics and pharmacodynamics of vhx-896 and iloperidone and evaluate the safety and tolerability of vhx-896 and iloperidone in patients with schizophrenia or bipolar i disorder under steady state conditions.


Eligibility criteria:
inclusion criteria: * male or female patients 18 to 65 years of age (inclusive) * diagnosed with either schizophrenia or bipolar i disorder, manic or mixed type, according to the diagnostic and statistical manual of mental disorder, fifth edition, text revision (dsm-5-tr) * patients must be symptomatically stable and on a stable treatment with an oral atypical antipsychotic at an adequate dose (3 months prior to enrollment) and not suffer from acute increase of their psychosis or be hospitalized within the past 2 months exclusion criteria: * history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes * cytochrome p450 2d6 (cyp2d6) poor metabolizers and use of prescription medication or otc medication that strongly inhibits cyp2d6 or cyp3a4 or induces cyp3a4 within 5 half-lives of baseline

Keywords: iloperidone vhx-896
study to evaluate qls-101 compared to timolol maleate eye drops in subjects with high eye pressure (glaucoma or ocular hypertension).

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: evaluating the safety and tolerability of qls-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.

multi-site study to evaluate the safety and tolerability of 3 concentrations of qls-101 versus timolol maleate preservative free (pf) 0.5% ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension

Eligibility criteria:
inclusion criteria: 1. visual acuity +1.0 logmar or better 2. willing to give informed consent 3. ability to washout from current intraocular pressure lowering medications - exclusion criteria: 1. severe glaucomatous damage 2. previous glaucoma intraocular or laser surgery 3. refractive surgery 4. ocular infection or inflammation

Keywords: elevated intraocular pressure